promestriene

ApprovedSmall molecule

UUniversity of Sao Paulo General Hospital

promestriene is one of 71 small molecule programs targeting Pelvic Organ Prolapse. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pelvic Organ ProlapseActive, not recruiting

AtrophyActive, not recruiting

Breast CancerActive, not recruiting

Pelvic Organ ProlapseApproved

Active, not recruiting

AtrophyPreclinical

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

promestriene

UUniversity of Sao Paulo General Hospital

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Avastin

BBio-Thera Solutions

Preclinical

153 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Adenocard

Astellas

Preclinical

1 6

Voltaren

Novartis

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Post-ApprovalRecruiting

Vaginal Dryness

NCT07153276

Clinical

Trials by Indication[1]

Complication1 trial

Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications

Completed·HHospices Civils de Lyon·Phase 3·NCT01370798·244 enrolled

Breast Cancer1 trial

LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)

Active, not recruiting·FFederal University of São Paulo·N/A·NCT04081805·195 enrolled

Pelvic Organ Prolapse1 trial

Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients

Completed·UUniversidade Federal do Paraná·Phase 4·NCT03032848·69 enrolled

Vaginal Dryness1 trial

TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE

Recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT07153276·60 enrolled

Atrophy1 trial

Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment

Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT04717245·75 enrolled

1 more indication

Acceptability1 trial

Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream

Completed·IInstituto Palacios·Phase 3·NCT04232813·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for promestriene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — promestriene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for promestriene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Sao Paulo General Hospital

promestriene

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Complication1 trial

Breast Cancer1 trial

Pelvic Organ Prolapse1 trial

Vaginal Dryness1 trial

Atrophy1 trial

Acceptability1 trial

References

Drug Info

Quick Facts

Related News